Hetal S Shah1,2, Lorena Ortega Moreno3,4, Mario Luca Morieri5, Yaling Tang1,2, Christine Mendonca1, Jenny Marie Jobe1, Jonathan B Thacker6, Joanna Mitri2, Stefano Monti7, Monika A Niewczas1,2, Subramaniam Pennathur6, Alessandro Doria1,2. 1. Section on Genetics and Epidemiology, Research Division, Joslin Diabetes Center, Boston, MA. 2. Department of Medicine, Harvard Medical School, Boston, MA. 3. Department of Basic Health Sciences, Universidad Rey Juan Carlos, Alcorcón, Spain. 4. High Performance Research Group in Physiopathology and Pharmacology of the Digestive System (NeuGut), Universidad Rey Juan Carlos, Alcorcón, Spain. 5. Department of Medicine, University of Padova, Padova, Italy. 6. Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI. 7. Computational Biomedicine, Department of Medicine, Boston University, Boston, MA.
Abstract
OBJECTIVE: To identify novel biomarkers of cardiovascular disease (CVD) risk in type 2 diabetes (T2D) via a hypothesis-free global metabolomics study, while taking into account renal function, an important confounder often overlooked in previous metabolomics studies of CVD. RESEARCH DESIGN AND METHODS: We conducted a global serum metabolomics analysis using the Metabolon platform in a discovery set from the Joslin Kidney Study having a nested case-control design comprising 409 individuals with T2D. Logistic regression was applied to evaluate the association between incident CVD events and each of the 671 metabolites detected by the Metabolon platform, before and after adjustment for renal function and other CVD risk factors. Significant metabolites were followed up with absolute quantification assays in a validation set from the Joslin Heart Study including 599 individuals with T2D with and without clinical evidence of significant coronary heart disease (CHD). RESULTS: In the discovery set, serum orotidine and 2-piperidinone were significantly associated with increased odds of incident CVD after adjustment for glomerular filtration rate (GFR) (odds ratio [OR] per SD increment 1.94 [95% CI 1.39-2.72], P = 0.0001, and 1.62 [1.26-2.08], P = 0.0001, respectively). Orotidine was also associated with increased odds of CHD in the validation set (OR 1.39 [1.11-1.75]), while 2-piperidinone did not replicate. Furthermore, orotidine, being inversely associated with GFR, mediated 60% of the effects of declining renal function on CVD risk. Addition of orotidine to established clinical predictors improved (P < 0.05) C statistics and discrimination indices for CVD risk (ΔAUC 0.053, rIDI 0.48, NRI 0.42) compared with the clinical predictors alone. CONCLUSIONS: Through a robust metabolomics approach, with independent validation, we have discovered serum orotidine as a novel biomarker of increased odds of CVD in T2D, independent of renal function. Additionally, orotidine may be a biological mediator of the increased CVD risk associated with poor kidney function and may help improve CVD risk prediction in T2D.
OBJECTIVE: To identify novel biomarkers of cardiovascular disease (CVD) risk in type 2 diabetes (T2D) via a hypothesis-free global metabolomics study, while taking into account renal function, an important confounder often overlooked in previous metabolomics studies of CVD. RESEARCH DESIGN AND METHODS: We conducted a global serum metabolomics analysis using the Metabolon platform in a discovery set from the Joslin Kidney Study having a nested case-control design comprising 409 individuals with T2D. Logistic regression was applied to evaluate the association between incident CVD events and each of the 671 metabolites detected by the Metabolon platform, before and after adjustment for renal function and other CVD risk factors. Significant metabolites were followed up with absolute quantification assays in a validation set from the Joslin Heart Study including 599 individuals with T2D with and without clinical evidence of significant coronary heart disease (CHD). RESULTS: In the discovery set, serum orotidine and 2-piperidinone were significantly associated with increased odds of incident CVD after adjustment for glomerular filtration rate (GFR) (odds ratio [OR] per SD increment 1.94 [95% CI 1.39-2.72], P = 0.0001, and 1.62 [1.26-2.08], P = 0.0001, respectively). Orotidine was also associated with increased odds of CHD in the validation set (OR 1.39 [1.11-1.75]), while 2-piperidinone did not replicate. Furthermore, orotidine, being inversely associated with GFR, mediated 60% of the effects of declining renal function on CVD risk. Addition of orotidine to established clinical predictors improved (P < 0.05) C statistics and discrimination indices for CVD risk (ΔAUC 0.053, rIDI 0.48, NRI 0.42) compared with the clinical predictors alone. CONCLUSIONS: Through a robust metabolomics approach, with independent validation, we have discovered serum orotidine as a novel biomarker of increased odds of CVD in T2D, independent of renal function. Additionally, orotidine may be a biological mediator of the increased CVD risk associated with poor kidney function and may help improve CVD risk prediction in T2D.
Authors: Yuji Okura; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: Svati H Shah; Jie-Lena Sun; Robert D Stevens; James R Bain; Michael J Muehlbauer; Karen S Pieper; Carol Haynes; Elizabeth R Hauser; William E Kraus; Christopher B Granger; Christopher B Newgard; Robert M Califf; L Kristin Newby Journal: Am Heart J Date: 2012-05 Impact factor: 4.749
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Natalia Nowak; Jan Skupien; Adam M Smiles; Masayuki Yamanouchi; Monika A Niewczas; Andrzej T Galecki; Kevin L Duffin; Matthew D Breyer; Nick Pullen; Joseph V Bonventre; Andrzej S Krolewski Journal: Kidney Int Date: 2018-02-02 Impact factor: 10.612
Authors: S Rizza; M Copetti; C Rossi; M A Cianfarani; M Zucchelli; A Luzi; C Pecchioli; O Porzio; G Di Cola; A Urbani; F Pellegrini; M Federici Journal: Atherosclerosis Date: 2013-11-18 Impact factor: 5.162
Authors: Andrea Ganna; Samira Salihovic; Johan Sundström; Corey D Broeckling; Asa K Hedman; Patrik K E Magnusson; Nancy L Pedersen; Anders Larsson; Agneta Siegbahn; Mihkel Zilmer; Jessica Prenni; Johan Arnlöv; Lars Lind; Tove Fall; Erik Ingelsson Journal: PLoS Genet Date: 2014-12-11 Impact factor: 5.917
Authors: Monika A Niewczas; Anna V Mathew; Stephanie Croall; Jaeman Byun; Melissa Major; Venkatta S Sabisetti; Adam Smiles; Joseph V Bonventre; Subramaniam Pennathur; Andrzej S Krolewski Journal: Diabetes Care Date: 2017-01-13 Impact factor: 19.112